Meeting
2024 ASCO Annual Meeting
Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study.
Authors
Nicolas Girard
Institut Curie, Paris, France
Nicolas Girard , Tae Min Kim , Hye Ryun Kim , Herbert H. Loong , Yuki Shinno , Shun Lu , Yong Fang , Jun Zhao , Kazumi Nishino , Ki Hyeong Lee , Liyun Miao , Tomohiro Sakamoto , Enriqueta Felip , Tsung-Ying Yang , Christophe Alfons Dooms , Daniel Shao-Weng Tan , Xiuning Le , Jan Christoph Brase , Paolo Grassi , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05099172
Citation
J Clin Oncol 42, 2024 (suppl 17; abstr LBA8598)
DOI
10.1200/JCO.2024.42.17_suppl.LBA8598
Abstract #
LBA8598
Poster Bd #
462
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).
First Author: Kazuto Nishio
Poster
2020 ASCO Virtual Scientific Program
ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).
First Author: Ji-Youn Han
Poster
2020 ASCO Virtual Scientific Program
MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA.
First Author: Emily S. Lebow
Poster
2017 Gastrointestinal Cancers Symposium
Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma.
First Author: Steven Brad Maron